Clinical Trial Search

Primary: Dichotomized, Adjudicated Modified Rankin Scale Score 0-3 vs. 4-6 at 365 Days Post Ictus (Adjusted) — 110; 100; 139; 140 Participants — p=0.73

Primary: Response Rate (RR) Achieved After Cycle 6 With RTXM83 Plus CHOP Compared to the RR Obtained With Mabthera® Plus CHOP (R-CHOP) in Patients With DLBCL — 83.6; 82.9; 84.7…

Primary: Morning Pre-dose Trough FEV1 — 0.072; 0.069; 0.037 Liter

Primary: Total Combined Score — 3.62; 4.35 Units on a scale — p=<0.0001

Primary: Percentage of Participants With Hepatitis B Virus (HBV) DNA Levels ≥ 20 IU/mL at Week 48, as Determined by the Modified United States Food and Drug Administration (US…

Primary: Left Ventricular Strain — 0.2; 0.4 Percent change in circumference — p=0.5867

Primary: Change From Baseline in Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) Total Score Following First Treatment Cycle — -12.46; -13.99; -3.93 Units on a scale…

Primary: Change From Baseline in Morning Pre-dose Trough FEV1 at Week 24 (BFF MDI Versus FF MDI) — 0.036; 0.017; -0.003 Liter

Primary: Number of Participants Who Experienced the Composite of All-cause Death, Stroke (VARC-2), and Major Bleeding (ISTH) in the Edoxaban Group Compared With Vitamin K…

Primary: Phase A: Number of Subjects With Confirmed Varicella Case — 37; 243; 201 Participants — p=<0.0001

Primary: Progression-free Survival(PFS) Rate — 7; 22; 42; 13 Participants — p=<0.001

Primary: Median Time to Onset of Nasal Symptom Relief as Assessed by Participant Diary Responses — 35.9; 72.0 Hours — p=<0.01

Primary: Long-term Safety of Zoledronic Acid for the Treatment of Osteoporotic Children Treated With Glucocorticoids. — 7; 12; 3; 0 Participants

Primary: Urinary Continence Recovery — 25; 5 grams

Primary: Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 90.1; 7.9 percentage of participants